Edition:
United Kingdom

Assertio Therapeutics Inc (ASRT.OQ)

ASRT.OQ on NASDAQ Stock Exchange Global Select Market

3.07USD
14 Jun 2019
Change (% chg)

$-0.25 (-7.53%)
Prev Close
$3.32
Open
$3.31
Day's High
$3.31
Day's Low
$3.06
Volume
109,573
Avg. Vol
216,563
52-wk High
$9.48
52-wk Low
$2.88

Latest Key Developments (Source: Significant Developments)

Assertio Therapeutics Reports Qtrly Adjusted Earnings Per Share $0.23
Wednesday, 8 May 2019 

May 8 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS ANNOUNCES FIRST-QUARTER 2019 FINANCIAL RESULTS.ASSERTIO THERAPEUTICS INC - RAISES 2019 EARNINGS GUIDANCE RANGE AND CONFIRMS NEUROLOGY FRANCHISE NET SALES GUIDANCE.ASSERTIO THERAPEUTICS INC - REPORTS QTRLY NEUROLOGY FRANCHISE NET SALES OF $26.3 MILLION.ASSERTIO THERAPEUTICS INC - QTRLY COMMERCIALIZATION AGREEMENT REVENUES OF $30.9 MILLION.ASSERTIO THERAPEUTICS INC - TOTAL QTRLY REVENUES $57.9 MILLION.ASSERTIO THERAPEUTICS INC - QTRLY TOTAL NON-GAAP REVENUE $59.7 MILLION.ASSERTIO THERAPEUTICS INC - QTRLY GAAP LOSS PER SHARE $0.22.ASSERTIO THERAPEUTICS INC - QTRLY ADJUSTED EARNINGS PER SHARE $0.23.ASSERTIO THERAPEUTICS INC - AS OF MARCH 31, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS OF $109.7 MILLION.ASSERTIO THERAPEUTICS INC - SEES 2019 NEUROLOGY FRANCHISE NET SALES LOW TO MID-SINGLE DIGIT GROWTH.ASSERTIO THERAPEUTICS INC - SEES 2019 GAAP NET LOSS $68 MILLION TO $58 MILLION.ASSERTIO THERAPEUTICS INC - SEES 2019 ADJUSTED EBITDA $118 MILLION TO $128 MILLION.  Full Article

Assertio Therapeutics Announces Favorable NUCYNTA Patent Ruling
Thursday, 28 Mar 2019 

March 28 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS ANNOUNCES FAVORABLE NUCYNTA® PATENT RULING.ASSERTIO THERAPEUTICS - BASED ON COLLEGIUM'S CURRENT 2019 NUCYNTA FRANCHISE REVENUE GUIDANCE, CO EXPECTS SUCH ROYALTIES TO BE ABOUT $120 MILLION IN 2019.ASSERTIO THERAPEUTICS - WITH U.S. COURT'S RULING, CO EXPECTS MARKET EXCLUSIVITY UNTIL DEC. 2025 FOR NUCYNTA ER, NUCYNTA AND NUCYNTA ORAL SOLUTION.  Full Article

Assertio Therapeutics Announces Fourth-Quarter And Full-Year 2018 Financial Results
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.FILES NDA FOR LONG-ACTING COSYNTROPIN AND RECEIVES FDA NOTIFICATION OF ACCEPTANCE.ISSUES FULL-YEAR 2019 GUIDANCE FOR EARNINGS AND NEUROLOGY FRANCHISE NET SALES.ISSUES FULL-YEAR 2019 GUIDANCE FOR EARNINGS AND NEUROLOGY FRANCHISE NET SALES.QTRLY GAAP LOSS PER SHARE $0.38.SEES 2019 NEUROLOGY FRANCHISE NET SALES LOW-TO MID-SINGLE DIGIT GROWTH.QTRLY ADJUSTED EARNINGS PER SHARE $0.30.QTRLY TOTAL REVENUES $42.6 MILLION & NON-GAAP REVENUE $62.8 MILLION.SEES 2019 NON-GAAP ADJUSTED EBITDA $115 TO $125 MILLION.Q4 EARNINGS PER SHARE VIEW $0.20, REVENUE VIEW $60.9 MILLION -- REFINITIV IBES DATA.Q4 REVENUE VIEW $60.9 MILLION -- REFINITIV IBES DATA.SEES 2019 GAAP NET LOSS $71 MILLION TO $61 MILLION.Q4 INCLUDES A $21.3 MILLION ADJUSTMENT REVERSAL FOR NON-CASH VALUE ASSIGNED TO INVENTORY TRANSFERRED TO COLLEGIUM.  Full Article

Assertio Therapeutics Announces Amendment Of Its Senior Secured Credit Facility
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS ANNOUNCES AMENDMENT OF ITS SENIOR SECURED CREDIT FACILITY.ASSERTIO THERAPEUTICS INC - WILL ADD A TRAILING FOUR-QUARTER NET SALES COVENANT OF $195 MILLION.ASSERTIO THERAPEUTICS - AMENDED SENIOR SECURED CREDIT FACILITY WITH NEW TRAILING 12-MONTH DEBT-TO-ADJUSTED EBITDA RATIO THAT DECLINES OVER TIME.  Full Article

Assertio Therapeutics Inc Sees 2018 GAAP Net Income Of $40 Mln To $50 Mln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS INC - SEES 2018 GAAP NET INCOME OF $40 MILLION - $50 MILLION AND 2018 ADJUSTED EBITDA OF $145 MILLION - $155 MILLION - SEC FILING.  Full Article

Assertio Therapeutics Announces Submission Of NDA For FDA Approval Of Cosyntropin Depot
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS ANNOUNCES SUBMISSION OF NDA FOR FDA APPROVAL OF COSYNTROPIN DEPOT.ASSERTIO THERAPEUTICS - IF NDA SUCCESSFUL, WILL OFFER PATIENTS IN U.S. ALTERNATIVE DEPOT FORMULATION TO IMMEDIATE-RELEASE COSYNTROPIN BY EARLY 2020.  Full Article

Depomed Says Is Currently Engaged In Settlement Discussions With Purdue Pharma
Monday, 9 Jul 2018 

July 9 (Reuters) - Depomed Inc ::DEPOMED - ON JULY 9, 2018, DEPOMED INC ANNOUNCED THAT IT IS CURRENTLY ENGAGED IN SETTLEMENT DISCUSSIONS WITH PURDUE PHARMA L.P - SEC FILING.DEPOMED - DEPOMED IN DISCUSSIONS WITH PURDUE PHARMA IN CONNECTION WITH ONGOING PATENT INFRINGEMENT LITIGATION BETWEEN THE COMPANY AND PURDUE - SEC FILING.DEPOMED SAYS CASE & ANY PENDING MOTIONS HAVE BEEN ADMINISTRATIVELY TERMINATED, PENDING OUTCOME OF DISCUSSIONS BETWEEN CO & PURDUE.  Full Article

Starboard Value Cuts Stake In Depomed Inc To 4.3 Pct
Tuesday, 22 May 2018 

May 22 (Reuters) - Depomed Inc ::STARBOARD VALUE LP CUTS STAKE IN DEPOMED INC TO 4.3 PERCENT AS OF MAY 18 FROM PREVIOUS STAKE OF 6.1 PERCENT AS OF MAY 10 - SEC FILING.  Full Article

Depomed Q1 Earnings Per Share $0.48
Thursday, 10 May 2018 

May 10 (Reuters) - Depomed Inc ::ANNOUNCES FIRST-QUARTER 2018 FINANCIAL RESULTS.Q1 GAAP EARNINGS PER SHARE $0.48.Q1 REVENUE $128.4 MILLION.Q1 REVENUE VIEW $65.8 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $0.17 -- THOMSON REUTERS I/B/E/S.INC - CONFIRMS PREVIOUS 2018 GUIDANCE FOR NEUROLOGY FRANCHISE NET SALES AND NON-GAAP ADJUSTED EBITDA.QTRLY ADJUSTED EARNINGS PER SHARE $0.28.  Full Article

Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Depomed Inc ::DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL.DEPOMED INC - RELOCATION OF COMPANY HEADQUARTERS MID-2018.DEPOMED INC - TRANSACTION IS IMMEDIATELY ACCRETIVE AND IMPROVES 2018 EBITDA OUTLOOK.DEPOMED - PLANS TO RELOCATE ITS CORPORATE HEADQUARTERS FROM NEWARK, SOMETIME IN MID-2018 & IS CURRENTLY EVALUATING POTENTIAL MIDWEST & EAST COAST LOCATIONS.DEPOMED INC - COMPANY WILL REDUCE ITS STAFF BY 40% TO APPROXIMATELY 70 EMPLOYEES AND HEADQUARTERS OFFICE SPACE REQUIREMENT BY 50%.DEPOMED INC - EXPECTS TO SAVE APPROXIMATELY $10 MILLION ANNUALLY AS A RESULT OF HEADQUARTERS RESTRUCTURING AND RELOCATION.DEPOMED INC - WILL ELIMINATE ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING ON NUCYNTA.DEPOMED INC - BY ELIMINATING ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING CO TO REDUCE SG&A EXPENSES BY ABOUT $70 MILLION ON AN ANNUAL BASIS.DEPOMED INC - UNDER TERMS OF AGREEMENT, COLLEGIUM WILL COMMERCIALIZE BOTH NUCYNTA EXTENDED RELEASE AND NUCYNTA IMMEDIATE RELEASE.DEPOMED INC - DEPOMED WILL RECEIVE A ROYALTY RATE ON ALL NUCYNTA REVENUES BASED ON CERTAIN NET SALES THRESHOLDS.  Full Article

UPDATE 5-Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

NEW YORK, March 29 Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.